2,992
回編集
差分
ナビゲーションに移動
検索に移動
†covered by Public Health Insurance for asplenia===Efficacy of pneumococcal vaccines=== ===Effectiveness of pneumococcal vaccines=== ===Effectiveness against colonization=== ==Serotype replacement== ==Overwhelming Post-Splenectomy Infection (OPSI) and pnuemococcus==
→Effectiveness of pneumococcal vaccines
===History of Pneumococcal vaccines in Japan===
{|class="wikitable"
|+''Table updated on 25th Aug 2023''
|-
!style="width:4em" rowspan="2"|Year!style="width:8em;12em"|Brand namePPSV23!style="width:8em;12em"|Approval for childrenPCV7!style="width:8em;12em"|Introduction to childhood routine immunizationPCV13!style="width:8em;12em"|Approval for adultsPCV15!style="width:8em;12em"|Introduction to adult routine immunizationPCV20
|-
!PPSV23|ニューモバックスNP<br>Pneumovax NP|1988（昭和63年）<br>≥ 2 year|nil<sup>†</sup>Prevenar||Prevenar13||Vaxneuvance|1988（昭和63年）|nil<sup>†</sup>
|-
!1988<br>昭和63
|'''Approved'''<br>- 2yr≤<br>'''''Covered by Public Health Insurance'''''<br>- Asplenia|| || || || |
|-
!2009<br>平成21
| ||'''Approved'''<br>- 2mo≤ ≤9yr|| || ||
|-
!2010<br>平成22
| ||'''''Routinized'''''<br>- 2mo≤ ≤60mo (<5yr)|| || ||
|-
!2013<br>平成25
| ||'''Terminated''' and switched to PCV13||'''Approved'''<br>- 2mo≤ <6yr<br>'''''Routinized'''''<br>- 2mo≤ ≤60mo (<5yr)|| ||
|-
!2014<br>平成26
|'''''Routinized'''''<br>- at 65yr<br>- 60-64yr with specific chronic conditions|| ||'''Approved'''<br>- 65yr≤ at risk of IPD|| ||
|-
!2020<br>令和2
| || ||'''Approved'''<br>- 6yr≤ at risk of IPD|| ||
|-
!2022<br>令和4
| || || ||'''Approved'''<br>- elderly<br>- adults at risk of IPD||
|-
!2023<br>令和5
| || || ||'''Approved'''<br>- 2mo≤||''Submitted for approval''
|-
! !!PPSV23!!PCV7!!PCV13!!PCV15!!PCV20
|}
